Exploring Proximal and Distal Ultrasound-Guided Greater Occipital Nerve Block Approaches in Migraine: A Systematic Review and Meta-Analysis.

Pain PractSep 16, 2026
Clinical ResearchNeurology

Haneen Sabet, Ahmed Samir, Basant Lashin et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness and safety of ultrasound-guided greater occipital nerve block (US-GONB) in 658 migraine patients. Results indicated significant reductions in pain intensity (MD = -3.48 points) and monthly headache frequency (MD = -9.12 days). Proximal injections showed greater reductions in headache frequency compared to distal injections.

Key findings

  • US-GONB significantly reduced pain intensity by 3.48 points.
  • Monthly headache frequency decreased by 9.12 days after US-GONB.
  • Headache duration was reduced by 18.98 hours.
  • Adverse events were generally mild, with 80% experiencing loss of pinprick sensation in proximal injections.

Why it matters

The findings support the use of US-GONB as an effective intervention for managing migraine, potentially improving patient quality of life by reducing pain and headache frequency.

Source

PubMed · PMID 42743099

Published in Pain Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.